Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands
Ellen H.M. Moors,
Piret Kukk Fischer,
Wouter P.C. Boon,
Frank Schellen and
Simona O. Negro
Technological Forecasting and Social Change, 2018, vol. 128, issue C, 133-143
The article aims to understand the institutionalisation process of markets for innovative products. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin® (trastuzumab) for breast cancer and Tarceva® (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. We show that market access became institutionalised as part of the technological innovation system of the first-mover personalised medicine, i.e. the market was formed, paving the way for the later personalised medicine products.
Keywords: Market formation; Institutionalisation; Technological innovation system; Transition; Personalised cancer medicine (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:tefoso:v:128:y:2018:i:c:p:133-143
Access Statistics for this article
Technological Forecasting and Social Change is currently edited by Fred Phillips
More articles in Technological Forecasting and Social Change from Elsevier
Series data maintained by Dana Niculescu ().